CARB-X is seeking additional accelerators to expand support for its pipeline

Dear All:

It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements said to be imminent.

According to the press release, CARB-X is aiming to partner with additional accelerators in Europe, North America, and the rest of the world to support the Powered by CARB-X portfolio. Up to two accelerators from each of those regions will be selected. The new accelerators will provide a broad range of support to projects funded by CARB-X, address common support needs across projects, and help build the community of people dedicated to fighting drug resistant bacteria.

The new accelerators will be in addition to existing accelerators in the CARB-X network: California Life Sciences Institute (CLSI), RTI International, MassBio, and Wellcome Trust (which is both an accelerator and a funder).

To be considered, accelerator applicants must be a going concern and must be able to work in a fully non-dilutive model. You can find the full Request for Proposals (RFP) here. To apply, click here. And finally, the full press release can be found on line hereApplications are welcome until March 30, 2018.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • [UPDATED with link for 2018 program] 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) 

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top